Position Statement: Postmenopausal Osteoporosis Treatment Strategies in Korea

참고문헌 (39)

1. Demontiero O, "Aging and bone loss : new insights for the clinician", Ther Adv Musculoskelet Dis, 4, pp.61~76 (2012)[DOI]
2. Bliuc D, "Risk of subsequent fractures and mortality in elderly women and men with fragility fractures with and without osteoporotic bone density : the Dubbo Osteoporosis Epidemiology Study", J Bone Miner Res, 30, pp.637~646 (2015)[DOI]
3. Singer A, "Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States", Mayo Clin Proc, 90, pp.53~62 (2015)[DOI]
4. Camacho PM, "American association of clinical endocrinologists", american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update executive summary, 2020, pp.26, 564~570
5. Gregson CL, "UK clinical guideline for the prevention and treatment of osteoporosis", Arch Osteoporos, 17, pp.58~ (2022)[DOI]
6. Shoback D, "Pharmacological management of osteoporosis in postmenopausal women : an endocrine society guideline update", J Clin Endocrinol Metab, 105, pp.dgaa048~ (2020)[DOI]
7. National Institute for Health and Care Excellence, "Osteoporosis: Fragility fracture risk: Osteoporosis: Assessing the risk of fragility fracture", National Institute for Health and Care Excellence, ~ (2012)
8. 유제현, "Osteoporotic Fracture: 2015 Position Statement of the Korean Society for Bone and Mineral Research", 대한골대사학회지, 22(4), pp.175~181 (2015), 대한골대사학회
9. Zhou J, "Fall prevention and anti-osteoporosis in osteopenia patients of 80 years of age and older : a randomized controlled study", Orthop Surg, 12, pp.890~899 (2020)[DOI]
10. Välimäki MJ, "Effects of risedronate 5 mg", d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial, 2007, pp.29, 1937~1949
11. 김경욱, "The Efficacy of Selective Estrogen Receptor Modulators Monotherapies in Postmenopausal Women with Osteopenia", 대한골대사학회지, 29(3), pp.185~189 (2022), 대한골대사학회
12. Jolly EE, "Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years", Menopause, 10, pp.337~344 (2003)[DOI]
13. Tankó LB, "Oral weekly ibandronate prevents bone loss in postmenopausal women", J Intern Med, 254, pp.159~167 (2003)[DOI]
14. McClung MR, "Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis", J Bone Miner Res, 19, pp.11~18 (2004)[DOI]
15. Barrionuevo P, "Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women : a network meta-analysis", J Clin Endocrinol Metab, 104, pp.1623~1630 (2019)[DOI]
16. Black DM, "Effects of continuing or stopping alendronate after 5 years of treatment : the Fracture Intervention Trial Long-term Extension(FLEX) : a randomized trial", JAMA, 296, pp.2927~2938 (2006)[DOI]
17. Black DM, "The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis : a randomized extension to the HORIZON-Pivotal Fracture Trial(PFT)", J Bone Miner Res, 27, pp.243~254 (2012)[DOI]
18. Bone HG, "10 years of denosumab treatment in postmenopausal women with osteoporosis : results from the phase 3 randomised FREEDOM trial and open-label extension", Lancet Diabetes Endocrinol, 5, pp.513~523 (2017)[DOI]
19. Bone HG, "Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass", J Clin Endocrinol Metab, 96, pp.972~980 (2011)[DOI]
20. Zanchetta MB, "Significant bone loss after stopping long-term denosumab treatment : a post FREEDOM study", Osteoporos Int, 29, pp.41~47 (2018)[DOI]
21. Miller PD, "Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial", Bone, 43, pp.222~229 (2008)[DOI]
22. Tsourdi E, "Discontinuation of denosumab therapy for osteoporosis : a systematic review and position statement by ECTS", Bone, 105, pp.11~17 (2017)[DOI]
23. Brown JP, "Discontinuation of denosumab and associated fracture incidence : analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months(FREEDOM)trial", J Bone Miner Res, 28, pp.746~752 (2013)[DOI]
24. Tripto-Shkolnik L, "Fracture incidence after denosumab discontinuation : Real-world data from a large healthcare provider", Bone, 130, pp.115150~ (2020)[DOI]
25. Lyu H, "Delayed denosumab injections and fracture risk among patients with osteoporosis : a population-based cohort study", Ann Intern Med, 173, pp.516~526 (2020)[DOI]
26. Kendler D, "Bone mineral density after transitioning from denosumab to alendronate", J Clin Endocrinol Metab, 105, pp.e255~e264 (2020)[DOI]
27. Makras P, "The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis", Bone, 138, pp.115478~ (2020)[DOI]
28. Sølling AS, "Treatment with zoledronate subsequent to denosumab in osteoporosis : a randomized trial", J Bone Miner Res, 35, pp.1858~1870 (2020)[DOI]
29. Horne AM, "Bone loss after romosozumab", denosumab : effects of bisphosphonates, 2018, pp.103, 55~61
30. Ha J, "Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women", Osteoporos Int, 33, pp.1591~1599 (2022)[DOI]
31. Díez-Pérez A, "Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis : a systematic review and meta-analysis", Bone, 120, pp.1~8 (2019)[DOI]
32. Kendler DL, "32. Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial", Lancet, 391, pp.230~240 (2018)[DOI]
33. Lindsay R, "Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis", Arch Intern Med, 164, pp.2024~2030 (2004)[DOI]
34. Leder BZ, "Denosumab and teriparatide transitions in postmenopausal osteoporosis(the DATA-Switch study) : extension of a randomised controlled trial", Lancet, 386, pp.1147~1155 (2015)[DOI]
35. Cosman F, "Romosozumab treatment in postmenopausal women with osteoporosis", N Engl J Med, 375, pp.1532~1543 (2016)[DOI]
36. Lewiecki EM, "One year of romosozumab followed by two years of denosumab maintains fracture risk reductions : results of the FRAME extension study", J Bone Miner Res, 34, pp.419~428 (2019)[DOI]
37. Saag KG, "Romosozumab or alendronate for fracture prevention in women with osteoporosis", N Engl J Med, 377, pp.1417~1427 (2017)[DOI]
38. Langdahl BL, "Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial", Lancet, 390, pp.1585~1594 (2017)[DOI]
39. McClung MR, "Skeletal responses to romosozumab after 12 months of denosumab", JBMR Plus, 5, pp.e10512~ (2021)[DOI]

관련 논문AI추천